P/B
0,9
Rallybio
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
$84.8M
Market Cap • 11/6/2026
2020
(6 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
195,4
P/EBITDA
—
P/OCF
2,7
P/FCF
2,7
P/E
3,5
BVPS
17,1
EPS
4,7
Market Cap
Market Cap
84,8M
EV
-5,9M
EV/Revenue
-13,6
EV/EBITDA
0,2
EV/EBIT
0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,3%
Total Yield
-0,3%
Payout
0%
Retained Earnings
-269,3M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
6177,4%
D&A/EBITDA
0%
R&D/Revenue
1812,9%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
7,2%
% PPE
0%
% Goodwill
0%
ROE
34,5%
ROIC
—
Growth
CAGR Op. Income 5Y
-11%
Leverage
N.D./EBITDA
3,7
Debt/Equity
0%
Current Ratio
28,9
Quick Ratio
27,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!